For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

The US Food and Drug Administration (FDA) has approved the consumption of gene-edited pigs, developed by UK-based biotechnology firm Pig Improvement Company (PIC). The company used CRISPR ...

The US Food and Drug Administration (FDA ... its approval in 1946, DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has ...

This week, the Food and Drug Administration approved gene-edited pigs developed by PIC, a biotechnology company specializing in livestock genetics, for human consumption. The FDA granted the ...

Johnson & Johnson (J&J) has received approval from the US Food and Drug Administration for its FcRn blocker Imaavy ... J&J’s Imaavy is designed to block FcRn and reduce levels of circulating ...

The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine ...

The Jewel Patch Wearable Cardioverter Defibrillator. Credit: Element Science/Business Wire. The US Food and Drug Administration (FDA) has approved Element Science’s premarket approval application for ...

Brad now navigates a cursor with his tongue and clicks by clenching his jaw—breakthrough abilities that highlight the implant’s life-changing potential. With FDA approval now in hand, Neuralink is ...

The FDA ap­proved a new nasal spray for mi­graines that was de­vel­oped by Sat­suma Phar­ma­ceu­ti­cals.

The FDA approval for Atzumi is based on two clinical ... However, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration and ...

applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM (nipocalimab-aahu) for the treatment of people ages 12 and older who are living with antibody positive (AChR+ or MuSK+) ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain by 2 hours post-treatment in 34.2% of migraine attacks. The FDA has approved ...